ArticlePediatric blood & cancer2020
Expanding construct validity of established and new PROMIS Pediatric measures for children and adolescents receiving cancer treatment.
Article in Pediatric blood & cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- A Systematic Review of Self-Report Instruments for the Measurement of Anxiety in Hospitalized Children with Cancer.International journal of environmental research and public health · 2021Pooled it
- Diminished Quality of Life Despite Reduced Treatment in Children With B-Lymphoblastic Leukemia: Children's Oncology Group AALL0932.Pediatric blood & cancer · 2026Trial
- Scaling up symptom screening for routine use in pediatric oncology: provincial implementation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- The Canadian Fontan Connection (CANFON): Protocol for a National Lifespan Cohort of People Living With a Fontan Circulation.CJC pediatric and congenital heart disease · 2026Article
- Comparative analysis of pediatric depression measures in clinical sample: evaluation of the PROMIS pediatric depression short form.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Proof-of-Concept of Online-Only Enrollment for Collecting Longitudinal Patient-Reported Outcomes in Young Individuals With Congenital Heart Disease.CJC pediatric and congenital heart disease · 2025Article
- Defining and measuring tolerability in pediatric, adolescent, and young adult oncology: The essential voices.Cancer · 2025Review
- Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination.Journal of the National Cancer Institute · 2025Article
- Advancing Global Cancer Symptom Science: Insights and Strategies From the Inaugural Cancer Symptom Science Expert Meeting.Oncology nursing forum · 2025Article
- Advancing Global Cancer Symptom Science: Insights and Strategies from the Inaugural Cancer Symptom Science Expert Meeting.Seminars in oncology nursing · 2025Article
- Lack of Gender-Disaggregated Data for the Psychological Impact of ACL Injury on Adolescents.Journal of clinical medicine · 2025Review
- Metabolomic Associations With Fatigue and Physical Function in Children With Cancer: A Pilot Study.Biological research for nursing · 2025Article
- Differences in Consummatory but Not Anticipatory Reward Processing Predict Depressive Symptoms in Young Adult Women.Psychophysiology · 2025Article
- Article
- Assessing quality of life in childhood cancer survivors at risk for hearing loss: a comparison of HEAR-QL and PROMIS measures.Frontiers in oncology · 2024Article
- Agreement and disagreement between child-caregiver symptom and function reports in pediatric oncology.Pediatric blood & cancer · 2024Article
- Cross-Cultural Adaptation and Psychometric Properties of the Traditional Chinese Version of the Italian Spine Youth Quality of Life (ISYQOL) Questionnaire.Healthcare (Basel, Switzerland) · 2023Article
- Outcome Measures and Patient-Reported Metrics in Cancer Rehabilitation.Current oncology reports · 2023Review
- Health behavior profiles in young survivors of childhood cancer: Findings from the St. Jude Lifetime Cohort Study.Cancer · 2023Article
- A joint international consensus statement for measuring quality of survival for patients with childhood cancer.Nature medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundThe Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric measures were designed to assess symptoms and functioning in children and adolescents. The study goal was to evaluate the validity and responsiveness of the PROMIS Pediatric measures in a diverse cohort of children with cancer.
methodsChildren (7-18 years) from nine pediatric oncology hospitals completed surveys at 72 hours preceding treatment initiation (T1) and at follow-up (T2) approximately 7 to 17 days later for chemotherapy, and 4+ weeks later for radiation. Children completed PROMIS Pediatric measures (Mobility, Pain Interference, Fatigue, Depressive Symptoms, Anxiety, Psychological Stress), Memorial Symptom Assessment Scale (MSAS), and global impressions of change (GIC) questions on their symptoms and functioning at T2 reflecting on T1. Parents completed the Lansky Play-Performance Status (PPS) scale and medication list for their child.
resultsThe children (n = 482) were average age 12.9 years, 46% female, 60% Caucasian, and had diverse cancers and treatments. There were moderate to strong correlations between PROMIS Pediatric and MSAS, supporting convergent validity. In support for known-groups validity, the PROMIS Pediatric average scores were statistically different (P < 0.05) for most domains by PPS and if the child was on a medication (or not) for controlling a symptom. The PROMIS Pediatric measures were responsive over time in association with the GIC.
conclusionsIn a large, diverse sample of children and adolescents with cancer, there was strong evidence for the construct validity and responsiveness of the PROMIS Pediatric measures. This evidence supports PROMIS Pediatric measure use in pediatric oncology trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.